Back­ing Cannabis’ Anec­do­tal Ev­i­dence With Sci­ence

Why Medipure Phar­ma­ceu­ti­cals Inc. is the com­pany to watch

BC Business Magazine - - Medipure Pharmaceuticals Inc. -

There is no short­age of anec­do­tal claims from in­di­vid­u­als that cannabis lessens a va­ri­ety of their med­i­cal con­di­tions or symp­toms, such as anx­i­ety, in­som­nia and pain.

That's where Medipure Phar­ma­ceu­ti­cals Inc. comes in.

“We want to de­velop novel, safe and ef­fec­tive mol­e­cules, and for­mu­late them into med­i­cal prod­ucts that will be ef­fec­tive in the treat­ment of a vast va­ri­ety of health con­di­tions,” says Dr. John May­nard, Medipure's Med­i­cal Di­rec­tor who brings 43 years of clin­i­cal med­i­cal ex­pe­ri­ence to the com­pany.

“One of the things that at­tracted me to Medipure is that we want to be ad­vo­cates for our pa­tients,” he says.

Medipure Phar­ma­ceu­ti­cals is com­mit­ted to pro­vid­ing sci­en­tif­i­cally proven, safe and ef­fec­tive cannabi­noid-based al­ter­na­tives to the cur­rent arse­nal of pre­scrip­tion drugs. Their core prod­ucts tar­get spe­cific as­pects of treat­ment, in­clud­ing pain man­age­ment, mood dis­or­ders/anx­i­ety, nau­sea, ap­petite stim­u­la­tion, arthri­tis and der­ma­tol­ogy.

“There is a lot of con­cern and dis­com­fort in the med­i­cal com­mu­nity with the cur­rent en­vi­ron­ment of med­i­cal cannabis and dispensaries,” says Dr. May­nard.

Cannabi­noids are the active in­gre­di­ents of cannabis. They have shown high ther­a­peu­tic value; how­ever, the un­der­ly­ing molec­u­lar mech­a­nism has to be thor­oughly un­der­stood. The sci­en­tists and re­searchers at Medipure aren't study­ing mar­i­juana that's in­haled or in­gested. In­stead, they're look­ing at the spe­cific ther­a­peu­tic po­ten­tial and the molec­u­lar mech­a­nisms of in­di­vid­ual en­do­cannabi­noid reg­u­la­tors to learn where they can be most ef­fec­tive.

“It is the sci­ence and the re­search on the en­do­cannabi­noid sys­tem at the molec­u­lar level that sep­a­rates Medipure from other com­pa­nies in­volved with cannabis. Medipure will be suc­cess­ful be­cause it will address the sci­en­tific need re­quired to make le­git­i­mate, non-ad­dic­tive af­ford­able drugs for doc­tors, pa­tients, and other health-care com­mu­ni­ties,” says Dr. Ni­har R. Pandey, who as Chief Sci­en­tific Of­fi­cer ( CSO) brings 20 years of R&D ex­pe­ri­ence to the com­pany. He added that Medipure would like to pro­vide doc­tors with sci­en­tific data so they are con­fi­dent enough to write those pre­scrip­tions.

For an in­vestor, that's ap­peal­ing be­cause if Medipure can work with—or be an al­ter­na­tive to—cur­rent med­i­ca­tions that are ad­dic­tive or have con­cern­ing side ef­fects, such as those for anx­i­ety, de­pres­sion, in­som­nia, skin dis­or­ders, or Post Trau­matic Stress Disor­der, then the mar­ket po­ten­tial is huge.

“Plus, I think it's the right com­pany be­cause of its lead­er­ship,” adds Dr. May­nard, re­fer­ring to Medipure's Chief Ex­ec­u­tive Of­fi­cer Boris Weiss, who has played an in­stru­men­tal role in the de­vel­op­ment and roll-out of a num­ber of in­te­gral biomed­i­cal and biotech ven­tures.

“It's the right com­pany be­cause of the cred­i­ble re­searchers and sci­en­tists who are com­mit­ted to do­ing that work. It's the right com­pany be­cause of the re­searchers' re­la­tion­ships with other sci­en­tists through­out the coun­try and the globe. And it's the right time to try to take the con­fu­sion out of this very com­plex in­dus­try, and put sci­ence be­hind it.”

With its bench-to-bed­side R&D ap­proach, Medipure is com­mit­ted to pro­vid­ing safe, ef­fec­tive and af­ford­able pre­scrip­tions for pa­tients; the test­ing is rig­or­ous, but it is also worth­while.

For more in­for­ma­tion about Medipure Phar­ma­ceu­ti­cals Inc., please visit their web­site: medipurephar­ma­ceu­ti­cals.com

Dr. John May­nard, Medipure’s Med­i­cal Di­rec­tor, brings 43 years of clin­i­cal med­i­cal ex­pe­ri­ence to the com­pany.

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.